Arcus Biosciences (RCUS) News Today

BNP Paribas Financial Markets trimmed its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 67.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,640 shares of the company's stock after selling 7

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 26.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 685,025 shar

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) saw a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 6,160,000 shares, a drop of 22.1% from the June 15th total of 7,910,000 shares. Approximately 12.8% of the shares of the company are sold short. Based on an average daily volume of 704,400 shares, the days-to-cover ratio is currently 8.7 days.

Nordea Investment Management AB boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 26.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 259,372 shares of the company's stock after purchasing an additional 53,944 shares

Barclays decreased their price target on shares of Arcus Biosciences from $35.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday.

Vanguard Group Inc. grew its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,680,716 shares of the company's stock after purchasing an additio

Cantor Fitzgerald restated an "overweight" rating on shares of Arcus Biosciences in a research report on Friday.

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and seven have given a b

Arcus Biosciences (NYSE:RCUS) Shares Down 6.5%

Arcus Biosciences (NYSE:RCUS) Stock Price Down 4.9% Following Analyst Downgrade

Truist Financial cut their price objective on shares of Arcus Biosciences from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday.

Arcus Biosciences (NYSE:RCUS) Shares Down 5.3%

Octagon Capital Advisors LP lessened its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 5.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,868,000 shares of the company's stock after s

Arcus Biosciences (NYSE:RCUS) Stock Price Up 7.5%

Sectoral Asset Management Inc. decreased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 74.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 97,435 shares of the company's stock after sell

Campbell & CO Investment Adviser LLC acquired a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 62,894 shares of the company's s

Arcus Biosciences (NYSE:RCUS) Shares Gap Up to $15.07

Dimensional Fund Advisors LP lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 11.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,594,609 shares of the company's

Decheng Capital LLC bought a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 869,790 shares of the company's stock, valued at a

Arcus Biosciences (NYSE:RCUS) Trading Up 2.7%

Panagora Asset Management Inc. increased its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 130.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 228,996 shares of the company's st

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have issued a

Arcus Biosciences (NYSE:RCUS) Stock Price Up 9.3%

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research report issued on Wednesday, May 8th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.80) per share for the

Arcus Biosciences (NYSE:RCUS - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.92. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The company had revenue of $145.00 million for the quarter, compared to analysts' expectations of $28.77 million. During the same period last year, the company earned ($1.09) EPS. The firm's revenue for the quarter was up 480.0% compared to the same quarter last year.

Arcus Biosciences (NYSE:RCUS) Shares Gap Up Following Earnings Beat

Wedbush reissued an "outperform" rating and set a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday.